December 7, 2024

BREAKING NEWS

Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

Support Groups | Newsletter Sign Up | Donate Now

Home » Ask The Doctor » What is the PFS for those on ibrutinib who have reached U-MRD and took a drug holiday?

What is the PFS for those on ibrutinib who have reached U-MRD and took a drug holiday?

January 12, 2022

This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.

Ask the Doctor Question:

Answer: There are no data, but there are anecdotal reports of patients going years without further treatment.

Ask The Doctor

Recurrent COVID-19 in Chronic Lymphocytic Leukemia

Progression-Free and Overall Survival Correlation in Relapsed CLL

Acalabrutinib and Obinutuzumab for Frontline CLL Treatment

CLL Patients Recommended for Second 2024-25 COVID Vaccine

Vitamin D Associated with Longer Treatment-Free Survival in Early CLL

More Vitamin D in Early CLL Improves Treatment-Free Survival

CLL SOCIETY FAST FIND

One click to our most popular content.

UPCOMING
EVENTS

CLL SOCIETY
SUPPORT GROUPS

LIST OF
CLL HEALTHCARE PROVIDERS

OFFICIAL STATEMENTS AND GUIDELINES

CLL GLOSSARY

CLL SOCIETY
IN THE NEWS

ADVOCACY

QUICK LINKS

UPCOMING
EVENTS

CLL SOCIETY
SUPPORT GROUPS

LIST OF
CLL HEALTHCARE PROVIDERS

OFFICIAL STATEMENTS AND GUIDELINES

CLL GLOSSARY

CLL SOCIETY
IN THE NEWS

ADVOCACY

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Functional

Performance

Analytics

Others

What is the PFS for those on ibrutinib who have reached U-MRD and took a drug holiday?

Ask The Doctor

RECENT NEWS

Recurrent COVID-19 in Chronic Lymphocytic Leukemia

Progression-Free and Overall Survival Correlation in Relapsed CLL

Acalabrutinib and Obinutuzumab for Frontline CLL Treatment

CLL Patients Recommended for Second 2024-25 COVID Vaccine

Vitamin D Associated with Longer Treatment-Free Survival in Early CLL

More Vitamin D in Early CLL Improves Treatment-Free Survival

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT CLL SOCIETY

CONTACT